OrbiMed’s Audentes Therapeutics, Inc BOLD Stock Holding History

OrbiMed’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,588,069	Closed	-$44.6M	–	153
2019 Q3	$44.6M	Sell	1,588,069 -125,000	-7%	-$4.27M	0.85%	38
2019 Q2	$64.9M	Sell	1,713,069 -101,931	-6%	-$3.92M	1%	34
2019 Q1	$70.8M	Sell	1,815,000 -78,500	-4%	-$2.25M	1.1%	27
2018 Q4	$40.4M	Sell	1,893,500 -286,500	-13%	-$7.39M	0.75%	44
2018 Q3	$86.3M	Sell	2,180,000 -435,000	-17%	-$16.2M	1.04%	27
2018 Q2	$99.9M	Sell	2,615,000 -907,100	-26%	-$33.6M	1.19%	29
2018 Q1	$106M	Sell	3,522,100 -607,538	-15%	-$20.6M	1.31%	24
2017 Q4	$129M	Hold	4,129,638	–	–	1.63%	19
2017 Q3	$116M	Sell	4,129,638 -672,000	-14%	-$14.6M	1.11%	29
2017 Q2	$91.9M	Hold	4,801,638	–	–	0.96%	32
2017 Q1	$81.8M	Hold	4,801,638	–	–	0.93%	36
2016 Q4	$87.7M	Hold	4,801,638	–	–	1.12%	30
2016 Q3	$85.5M	Buy	+4,801,638	New	+$72.9M	0.97%	39

Other funds holding BOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

OrbiMed's BOLD Position: Q4 2019 in Review

OrbiMed sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 1,588,069 shares — an estimated $44.6M sold.

OrbiMed first reported a position in BOLD in Q3 2016 and held it in 13 quarters. The position peaked at $129M in Q4 2017. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

OrbiMed reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
OrbiMed sold 1,588,069 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $44.6M.
OrbiMed first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 13 quarters.
OrbiMed's Audentes Therapeutics, Inc position peaked at $129M in Q4 2017.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.